Crewe Advisors’s BioNTech BNTX Stock Holding History

Crewe Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75.3K	Hold	809	–	–	0.01%	378
2026 Q1	$71.9K	Hold	809	–	–	0.01%	338
2025 Q4	$77K	Hold	809	–	–	0.01%	318
2025 Q3	$79.8K	Hold	809	–	–	0.01%	324
2025 Q2	$86.1K	Hold	809	–	–	0.01%	235
2025 Q1	$73.7K	Hold	809	–	–	0.01%	232
2024 Q4	$92.2K	Hold	809	–	–	0.01%	217
2024 Q3	$96.1K	Hold	809	–	–	0.01%	236
2024 Q2	$65K	Hold	809	–	–	0.01%	330
2024 Q1	$74.6K	Buy	+809	New	+$77.6K	0.01%	314

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Crewe Advisors's BNTX Position: Q2 2026 in Review

Crewe Advisors held its BioNTech (BNTX) position steady in Q2 2026 at 809 shares worth $75.3K. The position accounts for 0.01% of the portfolio, ranked #378.

Crewe Advisors first reported a position in BNTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $96.1K in Q3 2024. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Crewe Advisors held 809 shares of BioNTech worth $75.3K as of Q2 2026.
Crewe Advisors left its BioNTech share count unchanged in Q2 2026.
BioNTech made up 0.01% of Crewe Advisors's portfolio in Q2 2026, its #378 holding.
Crewe Advisors first reported a position in BioNTech in Q1 2024 and has held it in 10 quarters since.
Crewe Advisors's BioNTech position peaked at $96.1K in Q3 2024.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.